The top five Russian biotech startups are Skolkovo residents

20 August 2018

GMP News

Rusbase, an independent website devoted to technology, business and investment, published a list of the top five most interesting biotech startups in Russia, and all are residents of the Skolkovo Foundation.

The Skolkovo Innovation Center is a modern complex near Moscow that aims to nurture development in IT, biomedical, energy, nuclear, and space sectors.

Here are the top five biotech startups based in Skolkovo:

ExoAtlet makes robotic exoskeletons that enable people who have lost the use of their legs to stand up, sit down, walk and go up and down stairs. In addition to helping people recover their mobility, regular training in an exoskeleton has been shown to improve the patient’s muscle tone and a range of other heath factors, as well as their self-confidence and overall wellbeing. ExoAtlet won the main prize at Skolkovo’s Startup Village in 2014 and became a resident of the foundation soon afterwards. The company launched sales of its exoskeletons in 2016, having conducted clinical trials and obtained a medical license for the product. In April this year, it raised investment of $5 million from Korea’s Cosmo and Company to expand its business to Europe, China and the U.S. The Korean company previously funded ExoAtlet’s development in Asia.

3D Smile is a system for straightening teeth without braces. A 3D scan is made of the patient’s teeth and a plan devised for straightening them, and then based on the scan, a series of personalized mouth guards is made using a 3D printer. The patient wears each mouth guard for two weeks before progressing to the next one, while checking back in with the dentist every two months. The system has been on sale in Russia since 2014, after obtaining certification from the Russian health authorities, and its turnover in 2016 was 35.5 million rubles, according to Rusbase.

Knomics has devised a home test for analysing the makeup of a person’s microbiome. A growing area of scientific research suggests that biomarkers in our guts could help doctors identify which patients will respond to which drugs better, and also make dietary recommendations to patients that would help to prevent the onset of diseases such as diabetes, obesity and cancer altogether. Knomics is working on helping people to adjust the balance of bacteria in their guts to keep them as healthy as possible. The company, which works from a lab inside the Skolkovo Technopark, won the third prize at the Pioneers Moscow competition to discover the best budding tech companies in 2016.

Neurochat helps people who have both speech and movement disorders, such as those who have suffered a severe stroke, to communicate with other people using a brain-computer interface. The user wears a headset that registers the electrical activity of the brain and transmits data to the user’s computer via Bluetooth. The system transforms the patient’s mental effort into specific commands for the computer keyboard, enabling people to type text without using their voice or other movements. It can also be used to control household appliances, adjust beds etc., and for users to interact with each other remotely in a brand new kind of social network for people in similar situations. The company says it takes just 12 minutes to master the system. Neurochat was recently named one of the 100 best inventions of Russia by Rospatent, the federal intellectual property service.

DRD Biotech has designed an express test that can diagnose strokes and other forms of brain damage in just a few minutes from a single drop of blood. The test can not only determine whether a patient has had a stroke, it also shows whether they are at near-term risk of suffering one. It can also be used to detect concussion and the risk of posttraumatic epilepsy. DRD, which also works from its own lab at the Skolkovo Technopark, won a Skolkovo grant that it used to develop a prototype test and to partially cover the cost of clinical trials. The company expects to obtain a license for its tests in Russia this year, and when the product reaches the market, it is expected to cost no more than $20.

Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more